Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.56 USD
Change Today -0.12 / -7.14%
Volume 223.3K
OGEN On Other Exchanges
As of 8:04 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/15/15 - $2.64
52 Week Low
06/2/15 - $0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. develops, markets, and sells oral probiotics products and antibiotics for humans and companion pets. The company develops and markets probiotic products comprising ProBiora3, ProBiora3, a blend of oral care probiotics that promote fresher breath, whiter teeth, and support oral health under the Evora and ProBiora brands. Its ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. The company’s products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140 and other homolog antibiotic products. The company markets and sells its products through direct-to-consumer channels, professional offices, and private label partnerships. It has collaboration agreement with Intrexon Corporation for the development and commercialization of the native strain of MU1140 and related homologs. The company, formerly known as Oragen, Inc., was founded in 1996 and is headquartered in Tampa, Florida.

12 Employees
Last Reported Date: 02/27/15
Founded in 1996

oragenics inc (OGEN) Top Compensated Officers

Interim Principal Executive Officer, Chief Fi...
Total Annual Compensation: $220.7K
Senior Vice President of Operations & Product...
Total Annual Compensation: $188.9K
Senior Vice President of Discovery Research
Total Annual Compensation: $194.1K
Compensation as of Fiscal Year 2014.

oragenics inc (OGEN) Key Developments

Intrexon Corporation and Oragenics Announce Exclusive Channel Collaboration

Intrexon Corporation and Oragenics announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. Under the terms of the agreement, Oragenics will have access to Intrexon's technologies and expertise to develop products for the treatment of oral mucositis or products containing genetically modified Lactococcus lactis expressing trefoil factors in the oral cavity, throat, and esophagus for a technology access fee and will reimburse Intrexon for the research and development costs. The agreement also provides for commercial and regulatory milestone payments to Intrexon, as well as a low double-digit percentage royalty based on the net sales from collaboration products.

Oragenics To Explore Strategic Alternatives For OTC Probiotic Products Business

The Board of Directors of Oragenics Inc. (AMEX:OGEN) has authorized the exploration of strategic alternatives with respect to the company’s over-the counter (‘OTC’) probiotic business. These alternatives could include joint ventures, strategic partnerships or alliances, a sale of the OTC probiotic products business or other possible transactions. Frederick Telling, Oragenics’ Chairman, said, “The board of directors and management team are committed to further enhancing value for all Oragenics shareholders. We believe it is a prudent time to explore strategic alternatives for this business unit as we concentrate and focus our efforts and resources on the ongoing collaborations we have with Intrexon Corporation for the development of our novel class of antibiotics known as lantibiotics and probiotics for treatment of diseases of the oral cavity.”

Oragenics Inc. Approves Change in Dr. Martin Handfield's Title from Vice President, Research and Development to Senior Vice President of Discovery Research

On December 5, 2014, Oragenics Inc. approved change in Dr. Dr. Martin Handfield's title from Vice President, Research and Development to Senior Vice President of Discovery Research.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $1.56 USD -0.12

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr262.50 SEK +8.00
BLIS Technologies Ltd $0.02 NZD -0.001
View Industry Companies

Industry Analysis


Industry Average

Valuation OGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.9x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at